## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Holly Prentice

Appl. No.: 10/532,197 (U.S. National

Phase of PCT/US2003/033433)

§371(c) Date: September 12, 2006

For: High Expression Locus Vector
Based on Ferritin Heavy Chain

Gene Locus

Confirmation No.: 8404

Art Unit: 1636

Examiner: To Be Assigned

Atty. Docket: 2159.0580001/EKS/LMB

## First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. This First Supplemental Information Disclosure Statement is a continuation of the Applicant's Information Disclosure Statement re-filed on September 12, 2006 in connection with the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) before the mailing date of a first Office Action on the merits. No statement or fee is required.

The documents were cited in a search report by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report that indicates the degree of relevance found by the foreign office is provided in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38.

Copies of documents FP4 and NPL16-NPL18 are submitted.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

- 3 -

Holly Prentice
Appl. No. 10/532,197
(U.S. National Phase of PCT/US2003/033433)

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Low M. Brandy

Lori M. Brandes

Agent for Applicant

Registration No. 57,772

Date:

11/14/06

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

606425\_1.DOC

Equivalent of Form PTO/SB/08A (07-06) for use through 09/30/2008, OMB 0651-0031

Approved for use through 09/30/2005, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known 10/532,197 (U.S. Nat'l Phase of Application Number FIRST SUPPLEMENTAL PCT/US2003/033433) 8371 Date September 12, 2006 INFORMATION DISCLOSURE First Named Inventor Holly Prentice STATEMENT BY APPLICANT 1636 Art Unit (Use as many sheets as necessary) Examiner Name To Be Assigned of Sheet 1 1 Attorney Docket Number 2159.0580001/EKS/LMB

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages
		Number-Kind Code <sup>2 (M Known)</sup>		Applicant of Cited Document	or Relevant Figures Appear
	<u> </u>				
			•		
			i i		"
				• • •	
				, , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

		Fo	REIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (ff known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	FP4	WO 02/097059 A2	12-05-2002	Chromos Molecular Systems, Inc.		
			•			
						$\vdash$

606395\_1.DOC

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

English language I railseation is autocities.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Co	Complete if Known		
FIRST S	SUPPLEM	ŒN:	ΓΑL	Application Number	10/532,197 (U.S. Nat'l Phase of PCT/US2003/033433)		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				§371 Date	September 12, 2006		
				First Named Inventor	Holly Prentice		
				Art Unit	1636		
` '			•	Examiner Name	To Be Assigned		
Sheet	1	of	1	Attorney Docket Number	2159.0580001/EKS/LMB		

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL16	European Search Report for Application No. 03777780.2-2401 PCT/US0333433 dated October 11, 2006, five (5) pages.	•
	NPL17	TORTI, et al., "The Molecular Cloning and Characterization of Murine Ferritin Heavy Chain, a Tumor Necrosis Factor-inducible Gene," The Journal of Biological Chemistry, Issue of September 5, 1988, pages 12638-12644, Volume 263, No. 25., The American Society for Biochemistry and Molecular Biology, Inc.	
	NPL18	TSUJI, et al., "FER-1, an Enhancer of the Ferritin H Gene and a Target of E1A-Mediated Transcriptional Repression," Molecular and Cellular Biology, September 1995, pages 5152-5164, Volume 15, No. 9., American Society for Microbiology.	
		•	

606388_1.De	OC		
Examiner		Date	
Signature	*	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.